Combined management of large aggressive central giant cell granuloma of the mandible: A case report  by Al-Jandan, Badr
The Saudi Journal for Dental Research (2015) 6, 157–160King Saud University
The Saudi Journal for Dental Research
www.ksu.edu.sa
www.sciencedirect.comCASE REPORTCombined management of large aggressive central
giant cell granuloma of the mandible: A case report* Tel.: +966 558808829.
E-mail addresses: baljandan@ud.edu.sa, baljandan@hotmail.com
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.sjdr.2014.12.003
2352-0035 ª 2014 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Badr Al-Jandan *Division of Oral and Maxillofacial Surgery, Department of Biomedical Dental Sciences, College of Dentistry,
University of Dammam, P.O. Box 41982, Dammam 31441, Saudi ArabiaReceived 26 September 2014; revised 15 November 2014; accepted 17 December 2014
Available online 24 December 2014KEYWORDS
Pre-operative
corticosteroids;
Decortication;
Post-operative
corticosteroidsAbstract The aim of this study is to report a case of large aggressive central giant cell granuloma
(CGCG) of the mandible treated with corticosteroids and surgery. A 22-year-old male presented
with painless progressive swelling in the chin region. Biopsy conﬁrmed the diagnosis of CGCG.
Management of the lesion was carried out in 3 phases. Phase-1 comprised of intra-lesional cortico-
steroids, phase-2 comprised of surgical management and phase-3 consisted of post-surgical intra-
lesional corticosteroid. In this extensive case, although intra-lesional corticosteroid was given
pre-operatively, there was no evidence of a reduction in size of the lesion both clinically and
radio-graphically. This case suggests that injection of a low dose of corticosteroids pre-operatively
may not be effective in such large aggressive CGCGs. Nevertheless, combined medical and surgical
management is always advantageous for extensive aggressive lesions in order to reduce the size and
thus minimize the need for mutilating bone resections and loss of teeth that ultimately result in func-
tional and esthetic defects.
ª 2014 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Central giant cell granuloma (CGCG) is a benign tumor that is
found exclusively in the maxilla andmandible. The ﬁrst descrip-
tion of this tumor was presented by Jaffe and recommendedsurgical management for these lesions.1 The etiology of this
lesion is unknown but it is assumed to occur by trauma or
inﬂammation.2 Its occasional aggressive behavior results in
extensive destruction of the region affected. Radiographic pre-
sentation of these lesions is not pathognomonic and features
vary fromwell- or ill-deﬁned unilocular tomultilocular expansile
radiolucencies with or without destruction of the cortical plates.
The oldest and conventional management of these tumors
is by curettage.3 En-bloc resection is also a well-known
modality of treatment which results in lowest recurrence rates
and has been resorted as treatment of choice for locally aggres-
sive CGCGs.4 However, aggressive surgery of the jaw necessi-
tates major reconstruction leading to morbidity in terms of
function and esthetics.
Figure 1 Pre-op orthopantomogram (OPG).
Figure 3 Pre-op CT [axial section].
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A 22-year-old male presented to our department, complaining
of a painless swelling in the chin region. It was non-tender with
progressive growth since one year. There was history of
trauma 15 years back. The medical history was non-contribu-
tory. On extra-oral clinical examination, a large, hard, smooth
and non-tender swelling was evident extending between two
angles of the mandible with no evidence of lymphadenopathy.
Intra-oral examination revealed a hard, non-tender vestibular
swelling extending from the mandibular right molar to the left
molar region with no signs of discharge. Panoramic radiogra-
phy revealed large multilocular radiolucency extending
between angles of the mandible (Fig. 1). Computerized tomog-
raphy (CT) showed an extensive multilocular radiolucent
lesion with areas of cortical bone expansion, erosion and per-
forations between angles of the mandible (Figs. 2 and 3).
Endocrinology assessment was done to rule out hyperparathy-
roidism. Assays of alkaline phosphatase, parathyroid
hormone, calcium and phosphorus were within the normalFigure 2 Pre-op 3D CT.
Figure 4 Photomicrograph at 20 · of hematoxylin- and eosin-
stained slides showing multinucleated giant cells (arrows).range. An incisional biopsy conﬁrmed the diagnosis of CGCG.
This was considered as an aggressive form of CGCG based on
clinical behavior and histopathologic ﬁndings (Fig. 4).
After overall consideration of the patient’s age and morbid-
ity after the surgical management of the lesion, the options of
less invasive combined therapy were discussed with the patient.
Figure 6 Post-op 6 months CT [axial section].
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(pre-surgical intra-lesional corticosteroids), weekly intra-
lesional steroid injections (1 ml of Triamcinolone acetonide
(Kenacort, Piramal health care, kilitch drugs limited, India)
40 mg + 2 ml normal saline + 1 ml lidocaine HCl (2%) with
epinephrine 1:100,000)were given for 6 weeks. This 40 mg in
4 ml was divided equally to 4 syringes and injected into the
lesion at 4 equidistant sites. At the end of the treatment
phase-1, the lesion remained the same clinically and radio-
graphically. The phase-2 management (surgical) initiated was
performed under general anesthesia (GA) after 1 month from
the end of phase-1. Extraction of right impacted 3rd molar,
2nd molar and grade III mobile lower incisors, surgical
curettage and decortication of the lesion was done through
an intraoral approach. The lower border was left intact and
the continuity of the mandible was preserved.
Finally, the phase-3 of the management protocol (postsur-
gical intra-lesional corticosteroids) involved 9 intra-lesional
steroid injections over a period of 12 weeks of the same
composition used in phase-1. However, the third phase of ther-
apy, using the same dose of triamcinolone resulted in gradual
regression of the lesion and regeneration of the osseous defect
by the end of 3rd phase (Figs. 5 and 6). The patient was then
referred to a prosthodontist for tooth rehabilitation. Five year
clinical and radiological follow up revealed complete
regeneration of the osseous defect with no signs of recurrence
(Figs. 7–9).
3. Discussion
Management of aggressive forms of CGCGs has always been a
challenging problem for oral and maxillofacial surgeons due to
their high recurrence rates. The high recurrence rate of 55–
62% following curettage was reported by Hutter et al.5 The
high recurrence rate results in repetitive and extensive surgical
management with a signiﬁcant functional and estheticFigure 5 Post-op 6 months 3D CT.
Figure 7 Post-op 5 years 3D CT.
Figure 8 Post-op 5 years CT [axial section].
Figure 9 Post-op 5 years orthopantomogram (OPG).
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tive management modalities using pharmacological agents like
corticosteroids, calcitonin and systemic interferon alpha have
been developed and reported with encouraging results.6
Intra-lesional corticosteroid injection as an alternative non-
surgical method for managing giant cell lesions was suggested
by Jacoway et al.7 Studies by Flanagan et al. indicated that
multinucleated cells in giant cell granulomas of the jaws are
osteoclasts and dexamethasone’s inhibition of osteoclast-like
cells in marrow cultures support the use of intra-lesional corti-
costeroid for CGCG’s. 8 Corticosteroids not only inhibit
osteoclast activity but also result in rapid resolution including
bone regeneration and the recovery of normal functioning.9
The technique is simple, cost effective and relatively quick
which avoids expressive esthetic and functional defects.10 In
our case, an attempt was made to check the efﬁcacy of intra-
lesional corticosteroids in such extraordinary large cases.
Phase-1 management with corticosteroids was unsuccessful
and lead to the initiation of phase-2 surgical management.
Intra-lesional steroids could be considered as a single
treatment modality in small-localized lesions, however, in the
present case due to the large extent and aggressive nature of
this lesion, the patient was planned for a surgical enucleation
and curettage prior to which intra-lesional steroid injection
was administered to decrease the lesion size which has been
demonstrated earlier by Nogueira et al.11
After completion of Phase-1 (intra-lesional steroid
injection), it was noticed that the response to this treatment
modality was unfavorable, likely due to the thickness and cor-
tical nature of the mandibular bone. In addition, the presence
of multiple lytic cavities and extensiveness of the lesion most
likely prevented the steroids to reach all planned areas espe-
cially the posterior lingual area.
At the end of phase-3, post-surgical corticosteroid therapy,
the lesion began to regress radiographically at a steady pace
for 6 months after the ﬁnal phase with no signs of recurrence
for about 5 years post operatively.
4. Conclusion
In our extensive case, although intra-lesional corticosteroid
was given pre-operatively, there was no evidence of reduction
in size of the lesion both clinically and radiographically. This
case suggests that injection of a low dose of corticosteroids
preoperatively may not be effective in such large aggressiveCGCGs. Nevertheless, combined medical and surgical man-
agement is always advantageous for extensive aggressive
lesions in order to reduce the size and thus minimize the need
for mutilating bone resections and loss of teeth that ultimately
result in functional and esthetic defects.
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